Acceptance of a COVID-19 vaccine and associated factors among pregnant women in China: a multi-center cross-sectional study based on health belief model
Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases. Methods: A multi-center cross-sectional study among pregnan...
Saved in:
| Published in | Human vaccines & immunotherapeutics Vol. 17; no. 8; pp. 2378 - 2388 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
03.08.2021
Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases.
Methods: A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance.
Results: Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1-79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20-2.93), western region (aOR = 2.73, 95% CI: 1.72-4.32), low level of education (aOR = 2.49, 95% CI: 1.13-5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03-2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01-1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36-3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23-10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36-3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28-29.80).
Conclusions: About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations. |
|---|---|
| AbstractList | : Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases.
A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance.
Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1-79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20-2.93), western region (aOR = 2.73, 95% CI: 1.72-4.32), low level of education (aOR = 2.49, 95% CI: 1.13-5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03-2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01-1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36-3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23-10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36-3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28-29.80).
About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations. Background : Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases. Methods: A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance. Results: Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1–79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20–2.93), western region (aOR = 2.73, 95% CI: 1.72–4.32), low level of education (aOR = 2.49, 95% CI: 1.13–5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03–2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01–1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36–3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23–10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36–3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28–29.80). Conclusions: About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations. Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases. Methods: A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance. Results: Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1-79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20-2.93), western region (aOR = 2.73, 95% CI: 1.72-4.32), low level of education (aOR = 2.49, 95% CI: 1.13-5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03-2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01-1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36-3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23-10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36-3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28-29.80). Conclusions: About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations. Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases. Methods: A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance. Results: Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1–79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20–2.93), western region (aOR = 2.73, 95% CI: 1.72–4.32), low level of education (aOR = 2.49, 95% CI: 1.13–5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03–2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01–1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36–3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23–10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36–3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28–29.80). Conclusions: About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations. Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases.Methods: A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance.Results: Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1-79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20-2.93), western region (aOR = 2.73, 95% CI: 1.72-4.32), low level of education (aOR = 2.49, 95% CI: 1.13-5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03-2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01-1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36-3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23-10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36-3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28-29.80).Conclusions: About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations.Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among pregnant women, a vulnerable population for vaccine-preventable diseases.Methods: A multi-center cross-sectional study among pregnant women was conducted in five provinces of mainland China from November 13 to 27, 2020. We collected sociodemographic characteristics, attitude, knowledge, and health beliefs on COVID-19 vaccination. Locally weighted scatterplot smoothing regression analysis was used to assess the trends of vaccination acceptance. Multivariable logistic regression was performed to identify factors related to vaccination acceptance.Results: Among the 1392 pregnant women, the acceptance rate of a COVID-19 vaccine were 77.4% (95%CI 75.1-79.5%). In the multivariable regression model, the acceptance rate was associated with young age (aOR = 1.87, 95% CI: 1.20-2.93), western region (aOR = 2.73, 95% CI: 1.72-4.32), low level of education (aOR = 2.49, 95% CI: 1.13-5.51), late pregnancy (aOR = 1.49, 95% CI: 1.03-2.16), high knowledge score on COVID-19 (aOR = 1.05, 95% CI: 1.01-1.10), high level of perceived susceptibility (aOR = 2.18, 95% CI: 1.36-3.49), low level of perceived barriers (aOR = 4.76, 95% CI: 2.23-10.18), high level of perceived benefit (aOR = 2.18, 95% CI: 1.36-3.49), and high level of perceived cues to action (aOR = 15.70, 95% CI: 8.28-29.80).Conclusions: About one quarters of pregnant women have vaccine hesitancy. Our findings highlight that targeted and multipronged efforts are needed to build vaccine literacy and confidence to increase the acceptance of a COVID-19 vaccine during the COVID-19 pandemic, especially for vulnerable populations. |
| Author | Sun, Fenglan Deng, Lixia Liu, Jue Han, Na Yuan, Chuanxiang Wang, Ruitong Tao, Liyuan Liu, Min Liu, Jihong Han, Chunhua |
| Author_xml | – sequence: 1 givenname: Liyuan orcidid: 0000-0003-3497-1326 surname: Tao fullname: Tao, Liyuan organization: Peking University Third Hospital – sequence: 2 givenname: Ruitong surname: Wang fullname: Wang, Ruitong organization: Peking University – sequence: 3 givenname: Na surname: Han fullname: Han, Na organization: Tongzhou Maternal and Child Health Hospital – sequence: 4 givenname: Jihong surname: Liu fullname: Liu, Jihong organization: The Second Affiliated Hospital of Kunming Medical University – sequence: 5 givenname: Chuanxiang surname: Yuan fullname: Yuan, Chuanxiang organization: Qianjiang Maternal and Child Health Hospital – sequence: 6 givenname: Lixia surname: Deng fullname: Deng, Lixia organization: Qianjiang Central Hospital – sequence: 7 givenname: Chunhua surname: Han fullname: Han, Chunhua organization: Qujing Maternal and Child Health Hospital – sequence: 8 givenname: Fenglan surname: Sun fullname: Sun, Fenglan organization: Shexian Maternal and Child Health Hospital – sequence: 9 givenname: Min surname: Liu fullname: Liu, Min organization: Peking University – sequence: 10 givenname: Jue orcidid: 0000-0002-1938-9365 surname: Liu fullname: Liu, Jue email: jueliu@bjmu.edu.cn organization: Peking University Health Science Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33989109$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks9u1DAQxiNUREvpI4B85JLFduzEAQm1Wv6tVKkXQNysiTPZdeXYi-1t1Tfhccl2tyvKAXyxNf7mNx7P97w48sFjUbxkdMaoom84q4WUTM445WzGVMtFxZ8UJ9t4KaX4cXQ4M3lcnKV0TafVUC7q-llxXFWtahltT4pfF8bgOoM3SMJAgMyvvi8-lKwlN2CM9UjA9wRSCsZCxp4MYHKIicAY_JKsIy49-Exuw4ieWE_mK-vh7QQaNy7b0qDPGImJIaUyock2eHAk5U1_RzpIEzF4skJweUU6dBYHMoYe3Yvi6QAu4dl-Py2-ffr4df6lvLz6vJhfXJZGViKX0HFJjWx4JfpetmzAAVlbt6rrWUsrpoRSvVFStLVolcSm6VjTMGAITHHVVafFYsftA1zrdbQjxDsdwOr7QIhLDTFb41BLOvEN68ygjBAcQLABKtp3SnHeUDOx3u9Y6003Yr_tPYJ7BH184-1KL8ONVqKRNa0mwOs9IIafG0xZjzYZdA48hk3SXHLFmqkRNUlf_VnrUORhtJNA7gT3fx9xOEgY1VsX6QcX6a2L9N5FU967v_KMzbCd2_Rk6_6bfb7Ltn4IcYTbEF2vM9y5EIc42cwmXf0b8Rv0N-Bo |
| CitedBy_id | crossref_primary_10_1080_21645515_2022_2138047 crossref_primary_10_3390_vaccines10020255 crossref_primary_10_1136_bmjopen_2022_066367 crossref_primary_10_1093_cdj_bsad020 crossref_primary_10_3390_jpm13010040 crossref_primary_10_1136_bmjopen_2022_061477 crossref_primary_10_3390_children10091466 crossref_primary_10_4236_pp_2024_155010 crossref_primary_10_1016_j_puhip_2022_100338 crossref_primary_10_1111_jog_16150 crossref_primary_10_1186_s12978_022_01383_0 crossref_primary_10_3389_fmed_2023_1178872 crossref_primary_10_1007_s11356_022_19484_5 crossref_primary_10_1016_j_ejogrb_2021_12_003 crossref_primary_10_2174_0126669587350876241024103135 crossref_primary_10_1186_s12905_023_02331_1 crossref_primary_10_1186_s12889_022_12969_5 crossref_primary_10_1097_MD_0000000000039053 crossref_primary_10_3390_covid4060050 crossref_primary_10_1016_j_cegh_2022_100982 crossref_primary_10_1080_10410236_2023_2258310 crossref_primary_10_3390_vaccines10122055 crossref_primary_10_1080_14760584_2022_2053677 crossref_primary_10_3390_vaccines10060842 crossref_primary_10_1371_journal_pone_0278694 crossref_primary_10_1080_21645515_2022_2091899 crossref_primary_10_1080_14760584_2022_2100766 crossref_primary_10_1080_21645515_2021_2016006 crossref_primary_10_3389_fpubh_2022_986916 crossref_primary_10_3390_vaccines10081369 crossref_primary_10_3389_fimmu_2022_973600 crossref_primary_10_1080_01443615_2022_2056831 crossref_primary_10_1080_21645515_2023_2254539 crossref_primary_10_3390_vaccines10050766 crossref_primary_10_3390_vaccines11040812 crossref_primary_10_54133_ajms_v5i_193 crossref_primary_10_3390_vaccines11040813 crossref_primary_10_3390_vaccines10122022 crossref_primary_10_1038_s41598_022_18497_x crossref_primary_10_3390_vaccines10010110 crossref_primary_10_1002_ijgo_14646 crossref_primary_10_1177_20503121231159750 crossref_primary_10_3390_vaccines9121393 crossref_primary_10_54097_hset_v36i_6257 crossref_primary_10_1371_journal_pone_0296432 crossref_primary_10_3390_vaccines10081356 crossref_primary_10_59398_ahd_1399476 crossref_primary_10_1515_jpm_2022_0026 crossref_primary_10_54803_sauhsd_1234064 crossref_primary_10_3389_fpubh_2023_1236376 crossref_primary_10_3389_fpubh_2024_1286891 crossref_primary_10_2147_RMHP_S366730 crossref_primary_10_1016_j_pec_2023_107929 crossref_primary_10_3390_vaccines10010089 crossref_primary_10_18231_j_ijogr_2023_091 crossref_primary_10_1016_j_vaccine_2025_126835 crossref_primary_10_2147_PPA_S357653 crossref_primary_10_3389_fmed_2021_796208 crossref_primary_10_1136_bmjopen_2022_070551 crossref_primary_10_5993_AJHB_47_4_14 crossref_primary_10_3390_ijerph182413373 crossref_primary_10_4102_sajid_v38i1_516 crossref_primary_10_1590_1980_265x_tce_2022_0117pt crossref_primary_10_1080_21645515_2023_2186108 crossref_primary_10_1108_JFM_02_2023_0022 crossref_primary_10_3390_vaccines10091533 crossref_primary_10_1186_s12879_022_07856_8 crossref_primary_10_1055_a_1674_6120 crossref_primary_10_2147_IDR_S336486 crossref_primary_10_1016_j_ijid_2023_01_018 crossref_primary_10_3390_vaccines10101700 crossref_primary_10_1017_dmp_2023_142 crossref_primary_10_1038_s41372_023_01734_0 crossref_primary_10_54393_pjhs_v4i05_726 crossref_primary_10_3390_vaccines11030512 crossref_primary_10_1371_journal_pone_0305314 crossref_primary_10_1002_hsr2_70176 crossref_primary_10_1371_journal_pone_0269273 crossref_primary_10_1016_j_vaccine_2023_01_022 crossref_primary_10_1016_j_tmaid_2023_102667 crossref_primary_10_1038_s41541_024_00913_0 crossref_primary_10_1080_03630242_2022_2108194 crossref_primary_10_3389_fpubh_2022_995382 crossref_primary_10_1016_j_heliyon_2024_e26043 crossref_primary_10_5005_jp_journals_10006_2174 crossref_primary_10_1016_j_actpsy_2024_104254 crossref_primary_10_1080_10510974_2024_2439612 crossref_primary_10_2147_IJWH_S457740 crossref_primary_10_3390_vaccines12101153 crossref_primary_10_5005_jp_journals_10006_2178 crossref_primary_10_1093_infdis_jiad090 crossref_primary_10_1080_21645515_2025_2450131 crossref_primary_10_4103_mj_mj_2_23 crossref_primary_10_7759_cureus_30682 crossref_primary_10_33715_inonusaglik_1020271 crossref_primary_10_51847_tvmGc5ytyZ crossref_primary_10_1080_01443615_2022_2144174 crossref_primary_10_3389_fpubh_2022_1044193 crossref_primary_10_3390_vaccines11111697 crossref_primary_10_1136_bmj_2021_069741 crossref_primary_10_3389_fpubh_2023_1221788 crossref_primary_10_1080_21645515_2022_2151798 crossref_primary_10_1590_1980_265x_tce_2022_0117en crossref_primary_10_3389_fpubh_2022_825874 crossref_primary_10_1177_20503121231165670 crossref_primary_10_3389_fpubh_2023_1092724 crossref_primary_10_2147_PPA_S374217 crossref_primary_10_1080_21645515_2022_2140530 crossref_primary_10_3390_vaccines10020246 crossref_primary_10_4103_singaporemedj_SMJ_2021_259 crossref_primary_10_18601_16578651_n32_10 crossref_primary_10_1007_s40615_022_01434_z crossref_primary_10_1002_jgc4_1608 crossref_primary_10_1038_s41598_023_44370_6 crossref_primary_10_1016_j_reprotox_2022_10_003 crossref_primary_10_1186_s12884_022_04941_3 crossref_primary_10_1007_s11606_022_07588_0 crossref_primary_10_1016_j_outlook_2024_102196 |
| Cites_doi | 10.1111/phn.12600 10.1016/j.amepre.2015.06.009 10.1080/07370016.2011.539087 10.1016/j.cell.2020.09.040 10.1016/S1473-3099(20)30426-6 10.1016/j.vaccine.2018.10.049 10.15585/mmwr.mm6638a2 10.1016/j.vaccine.2020.12.074 10.3390/ijerph14121551 10.1016/j.vaccine.2014.01.081 10.1016/j.vaccine.2020.08.015 10.1016/j.vaccine.2016.01.056 10.1093/cid/ciy737 10.1016/S2468-2667(16)30001-9 10.3390/vaccines8040582 10.1080/21645515.2015.1027470 10.1080/21645515.2018.1483809 10.1016/j.vaccine.2015.08.093 10.1371/journal.pone.0215978 10.1177/109019818801500203 10.1093/cid/ciaa433 10.7326/M20-3569 10.1136/bmj.m3320 10.1016/j.ebiom.2016.08.042 10.1186/s12889-019-7172-8 10.1177/00333549111260S215 10.1016/j.vaccine.2020.09.041 10.1016/j.eclinm.2020.100522 10.15585/mmwr.mm6938e1 10.1016/S0140-6736(20)32318-7 10.1080/21645515.2019.1596713 10.1016/B978-0-12-802174-3.00026-6 10.1016/j.ajogmf.2020.100107 10.3760/cma.j.cn112137-20210104-00008 10.1016/S0140-6736(10)60421-7 10.1016/j.vaccine.2015.09.035 10.3390/vaccines8030482 10.3390/ijerph111212162 10.1017/S0950268816002491 |
| ContentType | Journal Article |
| Copyright | 2021 Taylor & Francis Group, LLC 2021 2021 Taylor & Francis Group, LLC 2021 Taylor & Francis |
| Copyright_xml | – notice: 2021 Taylor & Francis Group, LLC 2021 – notice: 2021 Taylor & Francis Group, LLC 2021 Taylor & Francis |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1080/21645515.2021.1892432 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | L. TAO ET AL |
| EISSN | 2164-554X |
| EndPage | 2388 |
| ExternalDocumentID | oai_doaj_org_article_5091fc1bcf8c442aa41fa30db882270c PMC8475603 33989109 10_1080_21645515_2021_1892432 1892432 |
| Genre | Research Article Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: National Science and Technology Key Projects on Prevention and Treatment of Major infectious disease of China grantid: 2020ZX10001002 – fundername: National Key Research and Development Project of China grantid: 2020YFC0846300; 2019YFC1710301 – fundername: National Natural Science Foundation of China grantid: 71874003 and 81703240 |
| GroupedDBID | --- 00X 0YH 30N 4.4 53G AALUX ABEIZ ABUPF ACENM ACGFS ADBBV ADCVX AECIN AENEX AEXWM AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG DGEBU DIK EBS H13 HYE IPNFZ KYCEM LJTGL M4Z O9- RIG RPM TDBHL TFL TFW TTHFI AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c534t-ab250c57234dd591fefe19698bd190318488dc854964985e77b1771a1ea1828b3 |
| IEDL.DBID | DOA |
| ISSN | 2164-5515 2164-554X |
| IngestDate | Wed Aug 27 01:29:00 EDT 2025 Thu Aug 21 18:34:49 EDT 2025 Fri Jul 11 04:46:55 EDT 2025 Thu Apr 03 07:06:50 EDT 2025 Thu Apr 24 23:03:43 EDT 2025 Tue Jul 01 02:46:14 EDT 2025 Wed Dec 25 09:06:36 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | COVID-19 vaccine hesitancy vaccine pregnant women acceptance |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c534t-ab250c57234dd591fefe19698bd190318488dc854964985e77b1771a1ea1828b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1938-9365 0000-0003-3497-1326 |
| OpenAccessLink | https://doaj.org/article/5091fc1bcf8c442aa41fa30db882270c |
| PMID | 33989109 |
| PQID | 2528174988 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2528174988 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8475603 pubmed_primary_33989109 informaworld_taylorfrancis_310_1080_21645515_2021_1892432 crossref_primary_10_1080_21645515_2021_1892432 doaj_primary_oai_doaj_org_article_5091fc1bcf8c442aa41fa30db882270c crossref_citationtrail_10_1080_21645515_2021_1892432 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-03 |
| PublicationDateYYYYMMDD | 2021-08-03 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human vaccines & immunotherapeutics |
| PublicationTitleAlternate | Hum Vaccin Immunother |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | e_1_3_4_4_1 e_1_3_4_3_1 e_1_3_4_2_1 e_1_3_4_9_1 e_1_3_4_8_1 e_1_3_4_42_1 e_1_3_4_7_1 e_1_3_4_20_1 e_1_3_4_41_1 e_1_3_4_6_1 e_1_3_4_40_1 e_1_3_4_5_1 e_1_3_4_23_1 e_1_3_4_46_1 e_1_3_4_24_1 e_1_3_4_45_1 e_1_3_4_21_1 e_1_3_4_44_1 e_1_3_4_22_1 e_1_3_4_43_1 e_1_3_4_27_1 e_1_3_4_28_1 e_1_3_4_49_1 e_1_3_4_25_1 e_1_3_4_26_1 e_1_3_4_47_1 e_1_3_4_29_1 Taylor MM (e_1_3_4_48_1) 2020; 2214 Lazarus JV (e_1_3_4_14_1) e_1_3_4_31_1 e_1_3_4_30_1 e_1_3_4_12_1 e_1_3_4_35_1 e_1_3_4_13_1 e_1_3_4_34_1 e_1_3_4_10_1 e_1_3_4_33_1 e_1_3_4_11_1 e_1_3_4_32_1 e_1_3_4_16_1 e_1_3_4_39_1 e_1_3_4_17_1 e_1_3_4_38_1 e_1_3_4_37_1 e_1_3_4_15_1 e_1_3_4_36_1 Blanchard-Rohner G (e_1_3_4_19_1) 2017; 147 e_1_3_4_18_1 |
| References_xml | – ident: e_1_3_4_2_1 – ident: e_1_3_4_21_1 doi: 10.1111/phn.12600 – ident: e_1_3_4_8_1 doi: 10.1016/j.amepre.2015.06.009 – ident: e_1_3_4_28_1 doi: 10.1080/07370016.2011.539087 – ident: e_1_3_4_5_1 doi: 10.1016/j.cell.2020.09.040 – volume: 147 start-page: w14526 year: 2017 ident: e_1_3_4_19_1 article-title: Review of maternal immunisation during pregnancy: focus on pertussis and influenza publication-title: Swiss Med Wkly – volume: 2214 start-page: 30484 issue: 20 year: 2020 ident: e_1_3_4_48_1 article-title: Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action publication-title: Lancet Glob Health – ident: e_1_3_4_13_1 doi: 10.1016/S1473-3099(20)30426-6 – ident: e_1_3_4_36_1 doi: 10.1016/j.vaccine.2018.10.049 – ident: e_1_3_4_33_1 doi: 10.15585/mmwr.mm6638a2 – ident: e_1_3_4_49_1 doi: 10.1016/j.vaccine.2020.12.074 – ident: e_1_3_4_25_1 doi: 10.3390/ijerph14121551 – ident: e_1_3_4_41_1 doi: 10.1016/j.vaccine.2014.01.081 – ident: e_1_3_4_24_1 – ident: e_1_3_4_22_1 doi: 10.1016/j.vaccine.2020.08.015 – ident: e_1_3_4_45_1 doi: 10.1080/07370016.2011.539087 – ident: e_1_3_4_26_1 doi: 10.1016/j.vaccine.2016.01.056 – ident: e_1_3_4_31_1 doi: 10.1093/cid/ciy737 – ident: e_1_3_4_4_1 doi: 10.1016/S2468-2667(16)30001-9 – ident: e_1_3_4_11_1 doi: 10.3390/vaccines8040582 – ident: e_1_3_4_20_1 doi: 10.1080/21645515.2015.1027470 – ident: e_1_3_4_34_1 doi: 10.1080/21645515.2018.1483809 – ident: e_1_3_4_35_1 doi: 10.1016/j.vaccine.2015.08.093 – ident: e_1_3_4_46_1 – ident: e_1_3_4_38_1 doi: 10.1371/journal.pone.0215978 – ident: e_1_3_4_27_1 doi: 10.1177/109019818801500203 – ident: e_1_3_4_7_1 doi: 10.1093/cid/ciaa433 – ident: e_1_3_4_10_1 doi: 10.7326/M20-3569 – ident: e_1_3_4_43_1 doi: 10.1136/bmj.m3320 – ident: e_1_3_4_16_1 doi: 10.1016/j.ebiom.2016.08.042 – ident: e_1_3_4_17_1 doi: 10.1186/s12889-019-7172-8 – ident: e_1_3_4_29_1 doi: 10.1177/00333549111260S215 – ident: e_1_3_4_12_1 doi: 10.1016/j.vaccine.2020.09.041 – ident: e_1_3_4_6_1 – ident: e_1_3_4_32_1 doi: 10.1016/j.eclinm.2020.100522 – ident: e_1_3_4_42_1 doi: 10.15585/mmwr.mm6938e1 – ident: e_1_3_4_3_1 doi: 10.1016/S0140-6736(20)32318-7 – ident: e_1_3_4_18_1 doi: 10.1080/21645515.2019.1596713 – ident: e_1_3_4_40_1 doi: 10.1016/B978-0-12-802174-3.00026-6 – ident: e_1_3_4_44_1 doi: 10.1016/j.ajogmf.2020.100107 – ident: e_1_3_4_47_1 doi: 10.3760/cma.j.cn112137-20210104-00008 – ident: e_1_3_4_15_1 doi: 10.1016/S0140-6736(10)60421-7 – ident: e_1_3_4_23_1 doi: 10.1016/j.vaccine.2015.09.035 – ident: e_1_3_4_9_1 doi: 10.3390/vaccines8030482 – ident: e_1_3_4_37_1 doi: 10.3390/ijerph111212162 – ident: e_1_3_4_39_1 doi: 10.1017/S0950268816002491 – start-page: 225 ident: e_1_3_4_14_1 article-title: A global survey of potential acceptance of a COVID-19 vaccine publication-title: Nat Med – ident: e_1_3_4_30_1 |
| SSID | ssj0000702466 |
| Score | 2.5631695 |
| Snippet | Background: Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related... : Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related factors among... Background : Vaccine hesitancy has been recognized as an urgent public health issue. We aimed to explore the acceptance of a COVID-19 vaccine and related... |
| SourceID | doaj pubmedcentral proquest pubmed crossref informaworld |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2378 |
| SubjectTerms | acceptance China COVID-19 COVID-19 Vaccines Cross-Sectional Studies Female Health Belief Model Humans Pandemics Pregnancy Pregnant Women Research Paper SARS-CoV-2 Vaccination vaccine vaccine hesitancy Vaccines |
| Title | Acceptance of a COVID-19 vaccine and associated factors among pregnant women in China: a multi-center cross-sectional study based on health belief model |
| URI | https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1892432 https://www.ncbi.nlm.nih.gov/pubmed/33989109 https://www.proquest.com/docview/2528174988 https://pubmed.ncbi.nlm.nih.gov/PMC8475603 https://doaj.org/article/5091fc1bcf8c442aa41fa30db882270c |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxRBEG40IHgR346P0ILXTvo50-0tRkMUjBcjuTX9Gg3IbNhshPyT_FyremaX3SDsxWvPg66tmq6vtqu_j5B3IVhXpGtZCLEw3YrAnE6KacFD1LJkU_A08teT9vhUfzkzZ2tSX9gTNtIDjz_cPia0PomYepu0liFo0QfFcwRoKDuecPWFW9aKqboGd5B76kalhHqAASwwy-M7lu_jGA5BeSjFnrBQgyi5kZgqf_8t9tJ_YdDbrZRruenoIXkwgUp6MBrziNwpw2Nyb5SZvH5Cbg4SNq-gf-msp4Eefvvx-SMTjv4JCTfWaRgyDZOjSqaTCA-tSkT0Yl5-YrsMrWwN9HygVXT7PbyotiMynFWZ02oXu6y9XTidylxLMU1mOhvoeOKSxgKot6dVgecpOT369P3wmE2KDCwZpRcsREBMyXRS6ZwNOKb0Bfl1bMwALGB5gOUgJws1Z6udNaXrkN1KBFEC1DE2qmdkZ5gN5QWhKRrept45mTsdSx-yMy7z5HjhMibeEL10h08TXTmqZvz2YmI1XXrRoxf95MWG7K0euxj5OrY98AF9vboZ6bbrAAShn4LQbwvChrj1SPGL-m9LP0qjeLVlAm-XYeXh08b9mjCU2dWll0ZaKBidtQ15PobZappKOQtIzzWk2wjADTs2rwznvyp9OOARgLnq5f8w_BW5j7bUjkj1muws5lflDaC0RdwldxU_2a2f5V-d4TV8 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELZQEYIL70d4Gomrw_q1a3MrhaqFNlxa1JvlZ6lAmypNkOCX8HPxeHejJAL10OvuemNPvh1_Y4-_QeiNtUpHpmtirYtE1NQSLTwnglbWCRaDjHAa-XBS7x2LTyfyZOUsDKRVQgydOqGI4qvh44bF6CEl7i3LHD_P9DKHd4yOqcoxBM9u-LrUdQNVDHg1Wa6zZEizbssSWhFoNhzk-d-b1qaoouS_oWP6Lza6mVS5Mkvt3kF-GF-XnPJ9vJi7sf-9If14NQPcRbd7Eou3O9TdQ9diex_d6Mpa_nqA_mx7SJYBPOFpwhbvfPm6_4FQjX9aDxv5OP8ytj0wYsB90R9cKh_h81k8hfQcXNQh8FmLS5Hvd_lFJf2RwNjjDBfrkYuSSwbdKUq5GKblgKct7k54Yhczy064VPx5iI53Px7t7JG-AgTxkos5sS4zNC8bxkUIUtMUUwQ9H-VCJjLZHWX3E7zKMW4ttJKxaUBNi1oabY6blOOP0FY7beMThL2TVe2T1iw0wsVkg5Y6VF5XsWLOVyMkhj_d-F4eHap0_DC0V1EdjG7A6KY3-giNl83OO32Qyxq8B0QtHwZ573JhOjs1vbcwwOKSp84n5YVg1gqaLK-Cy_EQayo_QnoVj2ZeVndSV4rF8Es68HoAr8muBPaHbBuniwvDJFM5QNVKjdDjDszLbnKuVWaWeoSaNZivjWP9Tnv2rciVZ_6TaTV_eoU-v0I3944OD8zB_uTzM3QLbpUkTP4cbc1ni_giE8O5e1m-_L_xdFSZ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jj9MwFLbQIBAX9qWsRuLqEi9JbG7DDKMZlsKBQdwir8MIlFZdkOCX8HN5z0mqaQWaw1ybOrXdL8_fiz9_j5AX1moThamYtS4yVXHLjPKSKV5Yp0QMZcTTyB8m1eGxevu1HNSEi15WiTl06owicqzGh3sW0qCIeymA4sNCX0J2J_iYa0ghJEThyxWah-MpjmKyfs0CiBbdjiW2YthsOMfzvzttrFDZyH_LxvRfZHRbU3lmkTq4QdwwvE6b8n28Wrqx_73l_Hih8d8k13sKS3c7zN0il2J7m1zpilr-ukP-7HqUyiCa6DRRS_c-fjnaZ9zQn9bjNj6FH6a2h0UMtC_5Q3PdIzqbxxMU59DsDUFPW5pLfL-CG2XxI8OhxznNk8cWWUmG3ck-uRQX5UCnLe3Od1IXgWMnmuv93CXHB28-7x2yvv4D86VUS2Yd8DNf1kKqEErDU0wR3Xy0C0BjIBhB8AleQ4ZbKaPLWNfopcUtjxayJu3kPbLTTtv4gFDvyqLyyRgRauVissGUJhTeFLEQzhcjoob_vPG9OTrW6PjR8N5DdZj0Bie96Sd9RMbrZrPOHeS8Bq8RUOsvo7l3_mA6P2n6WNEgh0ueO5-0V0pYq3iysggOsiFRF35EzFk4Nsv8bid1hVgaeU4Hng_YbSCQ4O6QbeN0tWhEKTSkp0brEbnfYXndTSmNBl5pRqTeQPnGODavtKffslk5sB8g1fLhBfr8jFz9tH_QvD-avHtEruGVrMCUj8nOcr6KT4AVLt3T_Nz_BXRwUz0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acceptance+of+a+COVID-19+vaccine+and+associated+factors+among+pregnant+women+in+China%3A+a+multi-center+cross-sectional+study+based+on+health+belief+model&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Liyuan+Tao&rft.au=Ruitong+Wang&rft.au=Na+Han&rft.au=Jihong+Liu&rft.date=2021-08-03&rft.pub=Taylor+%26+Francis+Group&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=17&rft.issue=8&rft.spage=2378&rft.epage=2388&rft_id=info:doi/10.1080%2F21645515.2021.1892432&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5091fc1bcf8c442aa41fa30db882270c |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon |